Plus, news on Inductive Bio, AbelZeta Pharma, GPCR Therapeutics, Bridge Biotherapeutics and NextCure.
Apellis preempts EU rejection for eye drug: The company expects a negative opinion from the Committee for Medicinal Products for Human Use on pegcetacoplan, which is under review for the treatment of geographic atrophy secondary to age-related macular degeneration. The complement C5 inhibitor in February won US approval for the indication as Syfovre, but its launch has been plagued by real-world safety events. Apellis shares $APLS were down 20% on Thursday morning. — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.